Don’t Miss the Mark! How Secondary Pharmacology Can Affect Pharmaceutical Drug Development
Thursday, December 5, 2024
11:00 AM/PM to 12:30 PM (US EST, UTC -5)
Hosted by: The SOT Drug Discovery Toxicology and Computational Toxicology Specialty Sections and the British Toxicology Society
Registration required for this free webinar.
The SOT Drug Discovery Toxicology (DDTSS) and Computational Toxicology (CTSS) Specialty Sections, together with the British Toxicology Society Discovery Toxicology Specialty Section, are excited to jointly host a webinar on state-of-the-art in secondary pharmacology and its impact on the safety of new medicines. Secondary pharmacology screening of investigational small-molecule drugs for potentially adverse off-target activities has become standard practice in pharmaceutical research and development, and regulatory agencies are increasingly requesting data on activity against targets with recognized adverse effect relationships. However, the screening strategies and target panels used by pharmaceutical companies vary substantially. This webinar will feature Dr. Jean-Pierre Valentin (UCB Biopharma) and Friedemann Schmidt (Sanofi), both experienced safety scientists in the pharma industry, who will present on behalf of colleagues from the International Consortium for Innovation and Quality in Pharmaceutical Development Secondary Pharmacology Working Group. This event will be an exciting opportunity to learn about how secondary pharmacology assessment is being positioned today and in the future. Additionally, the discussion will include advances in secondary pharmacology technology and opportunities and challenges in this rapidly developing field.
Speaker(s):
· Jean-Pierre Valentin, PhD, HDR, ERT, CBiol, FSBiol, FRCPath, DSP, Head of Investigative Toxicology, UCB Biopharma SRL
· Friedemann Schmidt, PhD, Head of Digital Toxicology, Sanofi
Registration required for this free webinar.